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OBJECTIVES: Hemophilia B is a rare and expensive to treat disease. The aim of this
studywas to develop an economic evaluation of prophylactic vs on-demand supply
of recombinant factor IX (rFIX) in the treatment of patients with severe hemophilia
B, from the Social Security Mexican Institute (IMSS) perspective. METHODS: A
three-state Markovmodel (two-week cycles) followingmale patients from birth up
to 75 years was developed to estimate the cost and outcomes of prophylactic (30
IU/kg body weight/week) and on-demand (40 IU/kg body weight/joint bleed) ap-
proaches to manage haemophilia B. On-demand was considered the usual prac-
tice. Effectiveness measure was the QALY. A literature review was performed to
extract Mexican demographic and general epidemiologic data needed to populate
the model. Treatment cost data (inpatient, outpatient, emergency services, medi-
cines, laboratory and image studies) were extracted fromMexican published data-
bases (the acquisition cost of rFIX was provided by the manufacturer). Health and
economic consequences were assessed in different age groups. Both costs and
outcomes were discounted at 5% annual rate Probabilistic sensitivity analyses and
acceptability curves were constructed. RESULTS: Cost of rFIX in prophylaxis rep-
resented 60.3% and 90.4% of the total annual cost in the 4 years and 19 years
groups, respectively. In on-demand approach, the cost of the therapy represented
45.3% and 83.9% in the4 years and19 years group, respectively. The incremen-
tal effectiveness for rFIX is close to one QALY in all age groups. The ICER of pro-
phylaxis in patients 4, 5-9, 10-14, 15-19, 19 years old was US$5,281.33,
US$14,586, US$15,172, US$20,398 and US$40,291/QALY gained, respectively. Ac-
ceptability curves showed an inverse relationship between age and cost-effective
proportion.CONCLUSIONS:At IMSS setting, the prophylaxiswith rFIX for theman-
agement of patients suffering severe hemophilia B appears to be a highly cost-
effective and a cost-effective intervention in children and teenagers, respectively.
PSY31
ECONOMIC EVALUATION OF ELETRIPTAN 40MG FOR MIGRAINE THERAPY IN
KOREA
Kim HJ, Oh JJ, Park HJ, Ko SK
Pfizer Pharmaceuticals Korea Limited, Seoul, South Korea
OBJECTIVES: Migraine is a common central nervous system disorder. The burden
of migraine is substantial due to its high prevalence and prominent temporary
disability. This study investigates the application of cost-effectiveness analysis,
from the Korean health care system perspective, for the comparison of eletriptan
40mg and sumatriptan 50mg in the acute treatment ofmigraine attack.METHODS:
A decision tree model was developed to estimate migraine treatment cost and
efficacy. Clinical data was derived from a clinical trial comparing oral eletriptan to
oral sumatriptan (G. Sandrini, 2002). Efficacy measures consisted of “pain-free at 2
hours (PF2)” and “sustained pain free for 2-24 hours (SPF)”. Drug costs for initial
dosing, second dosing for relapse, physician visit cost, and emergency visit cost
were taken into account. Citing 2008 HIRA report, physician visit cost and emer-
gency visit cost were calculated. All costs converted into 2011 Korean Won (KRW).
The time horizonwas a singlemigraine attack. RESULTS: In the base-case analysis,
assuming the eletriptan 40mg drug cost (4,775 KRW) is 20% higher than su-
matriptan 50mg drug cost (3,979 KRW), the average cost-effectiveness ratio (ACER)
were 23,702 KRW and 36,239 KRW (per attack at which PF2 is achieved) for
eletriptan 40mg and sumatriptan 50mg, respectively. Also, ACER for SPF per attack
is achieved was 26,054 KRW and 40,837 KRW for eletriptan 40mg and sumatriptan
50mg, respectively. CONCLUSIONS: Although eletriptan 40mg is more costly than
sumatriptan 50mg, because of eletriptan 40mg’s superior efficacy, the ACER of
eletriptan 40mg was lower than sumatriptan 50mg in the treatment of migraine
attack, with respect to PF2 and SPF aspects. Eletriptan 40mg has a potentially im-
portant role to play in the cost-effective management of migraine.
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COST- EFFECTIVENESS ANALYSIS OF PARECOXIB IN THE MANAGEMENT OF
POSTSURGICAL PAIN IN MEXICO
Muciño-Ortega E, Galindo-Suárez RM
Pfizer S.A. de C.V., Mexico City, Mexico
OBJECTIVES: Pain management is an important dimension of postsurgical care.
The aim of this study was to determine the cost-effectiveness of parecoxib, mor-
phine, buprenorphine and ketorolac in themanagement of postsurgical pain, from
the perspective of the Mexican Social Security Institute (IMSS).METHODS: A deci-
sion-tree model was used to assess the outcomes of parecoxib 40mg; buprenor-
phine 0.12, 0.18 and 0.36mg;morphine 4, 6 and 12mg and ketorolac 30mg inwomen
who received them in the morning after their gynecologic surgery. In case of fail-
ure, rescue therapy with morphine 4mg was allowed. The time horizon is 12 hours
after the medication was received. Only the acquisition cost was considered (2011
US$). The effectiveness outcome was the proportion of respondents who experi-
enced onset of analgesia and rated their medication as “good” or “excellent”
(through patient=s global evaluation of the study medication questionnaire). Liter-
ature reviewwas performed to extract the clinical outcomes of competing alterna-
tives (the doses of morphine 4mg, buprenorphine 0.12mg and so on, were consid-
ered equianalgesic). Acquisition costs were extracted from official institutional
sources. The results of the analysis are expressed through the ICER (ketorolac as
basecase). Univariate sensitivity analysis was performed. RESULTS: The propor-
tion of respondents treated withmorphine 4mg-buprenorphine 0.12mg, morphine
6mg-buprenorphine 0.18mg, morphine 12mg-buprenorphine 0.36mg, ketorolac
and parecoxib was 44.21%; 44.21%; 46.42%; 63.64% and 71.76%, respectively. The
expected cost per patient ofmorphine 4mg, buprenorphine 0.12mg,morphine 6mg,
buprenorphine 0.18mg, morphine 12mg, buprenorphine 0.36mg, ketorolac and
parecoxib was $4.53; $1.45; $6.32; $1.71; $11.69; $2.48; $0.84 and $7.12, respectively.
All the alternatives (except parecoxib, ICER: $77.30) are dominated by ketorolac.
Furthermore, parecoxib ismore effective than competing alternatives but only less
expensive than morphine 12mg. CONCLUSIONS: At IMSS setting, parecoxib ap-
pears to be cost-saving regarding morphine 12mg and cost-effective regarding ke-
torolac, buprenorphine and morphine 4 and 6mg.
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ADAPTATION TO COLOMBIA AND VENEZUELA OF THE ECONOMIC MODEL
DASATINIB FIRST-LINE TREATMENT OF CHRONIC MYELOID LEUKEMIA,
DEVELOPED BY THE YORK HEALTH ECONOMICS CONSORTIUM
Orozco JJ1, Valencia JE2
1Universidad CES, Medellin, Colombia, 2Bristol-Myers Squibb Company, Bogota, Colombia
OBJECTIVES: Based on an economic evaluation of cost-effectiveness of frontline
dasatinib treatment for chronic myeloid leukemia by the York Consortium and
after transferability analysis of data, we performed an adaptation of this model in
Colombia and Venezuela. We compared the costs and cost-effectiveness ratio of
dasatinib 100 mg/day versus imatinib 400 mg/day and nilotinib 600 mg/day as
frontline treatment for CML in its three phases. with increases to 140 mg/day of
dasatinib, 800 mg/day of imatinib and 800 mg/day nilotinib in a second-line
therapy. METHODS: The original model considered those patients with CML who
had not received previous treatment and a Markov=s model with probabilities of
change for the chronic, accelerated and death phases, over the lifetime and with a
costs and benefits discount rates of 3.5%. Direct medical and treatment cost and
mortality rates were taken from the local jurisdiction and WHO life tables. The
results of the model included the costs of each alternative treatment with dasat-
inib, nilotinib or imatinib and the QALYs (Quality Adjusted Life Years). Costs are
expressed in 2011 Colombian pesos and Venezuelan strong bolivars. RESULTS:
Dasatinib 100 mg/day as frontline treatment for CML produced the greatest num-
ber of QALYs, both in Colombia and Venezuela with 10.67 and 10.53 QALYs respec-
tively, comparedwith imatinib; 10.10 and 9.97 QALYs and nilotinib; 10.50 and 10.36
QALYs Dasatinib 100 mg/day was also more cost-effective than nilotinib as front-
line treatment for CML, being dominant in both these countries. CONCLUSIONS: In
the frontline treatment for CML in Colombia and Venezuela, Dasatinib was more
effective than imatinib and nilotinb and showed better rates of cost-effective than
nilotinib been dominant in both countries. Although there was an increase in over-
all costs, this is due to the increase in life years gained and thus in greater use of
medical resources and medications.
PSY34
ASSESSING INTERVENTIONS FOR ADULTS WITH METABOLIC SYNDROME: A
COMPREHENSIVE ECONOMIC MARKOV DECISION MODEL
Castro M, Dequen P, Davies MJ, Khunti K, Abrams KR
University of Leicester, Leicester, UK
OBJECTIVES: Metabolic Syndrome (MetS) is defined as a clustering of risk factors
for diabetes mellitus (T2DM) and cardiovascular disease (CVD) which puts individ-
uals at increased risk of developing these conditions and consequently leads to a
reduction in life expectancy and increased morbidity. METHODS: A systematic
review and network meta-analysis was undertaken to assess the relative clinical
effectiveness of a number of lifestyle and pharmacological interventions, both
independently and in combination. A second systematic review, and series of
meta-analyses, was also undertaken to estimate the increased burden that a MetS
diagnosis has on the subsequent risk of T2DM, CVD and all-causemortality. A fully
probabilistic economic Markov decision model was developed in WinBUGS, and
which directly included the series of meta-analyses above, in order to assess the
cost-effectiveness of the various interventions. RESULTS: The use of both lifestyle
and pharmacological interventions in combination was dominated in the incre-
mental cost-effectiveness analysis, with the use of both of them independently
producing greater health gain at lower cost. Pharmacological intervention was
cost-effective compared to standard care (ICER £3050 with a probability of 0.53 at a
threshold value of £20K/QALY), and lifestyle intervention was cost-effective com-
pared to pharmacological (ICER £6933with a probability of 0.52 at a threshold value
of £20K/QALY). A series of sensitivity analyses were also undertaken both with
regards to the model inputs/distributions and a number of methodological as-
sumptions, but the results remained largely insensitive to these changes.
CONCLUSIONS: The use of a lifestyle intervention would appear to be a potentially
cost-effective treatment strategy for adults with MetS, however considerable un-
certainty surrounds this decision. The use of a comprehensive approach to eco-
nomic modelling within a WinBUGS framework allowed distributional assump-
tions to be relaxed, sources of correlation to be appropriately accounted for, and
more complex sensitivity analyses to be easily undertaken.
PSY35
ECONOMIC EVALUATION OF LENALIDOMIDE IN THE MANAGEMENT OF
PREVIOUSLY TREATED MULTIPLE MYELOMA (PTMM) PATIENTS IN GREECE
Fragoulakis V, Kourlaba G, Maniadakis N
National School of Public Health, Athens, Greece
OBJECTIVES: To assess the cost-effectiveness of lenalidomide with dexametha-
sone (Len/Dex) combination relative to bortezomib alone, in previously treated
multiple myeloma patients in Greece. METHODS: A discrete event simulation
model was locally adapted, to estimate the differences in the overall survival and
treatment cost for the two alternative options. Efficacy data utilized came from the
two large,multicenter, controlled, randomized clinical trials for the first option and
an open label study for the second. Quality of life data were extracted from inter-
national sources. Data on resource use and prices were collected from the elec-
tronic databases of local hospitals and other relevant sources. The perspective of
the analysis was that of payers. Total cost accounts for themonitoring and admin-
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istration of patients, the management of adverse events and the cost of medica-
tion. A 3.5% discount rate was used for the case of all outcomes. Monte Carlo
simulation was employed to construct the 95% uncertainty intervals (UI) and to
compute cost-effectiveness acceptability curve. RESULTS: The mean total QALYs
estimate in the Len/Dex armwas 2.95 (95%UI: 2.75-3.14) and 2.20 (95%UI: 1.99-2.40)
in the case of bortezomib, an incremental gain of 0.75 (95%UI: 0.47-1.02) QALYs. The
mean total therapy cost was estimated at €76,782 (95%UI: 75,689-€77,927) and
46.380€ (95%UI: 45,719€-47,000€) for Len/Dex and Bortezomib, respectively. For both
comparators, total therapy cost ismainly attributed tomedication. The cost per life
year gained was estimated at €35,081 (95%UI: €19,357-€73,180) and the cost per
QALY gained at €42,012 (95%UI: 29,445-64,217). The probability for Len/Dex to be a
cost-effective therapy option at a threshold three times the per capital income
(€60,000 per QALY), was higher than 95%. Results remained constant under several
one-way sensitivity analyses.CONCLUSIONS:Therefore therapywith combination
of Len/Dex appears to be a cost-effective choice compared with Bortezomib alone
for multiple myeloma patients in Greece.
PSY36
ECONOMIC EVALUATION OF PEGVISOMANT FOR ACTIVE ACROMEGALY
PATIENTS WHO FAILED AVAILABLE THERAPIES IN BRAZIL – PUBLIC HEALTH
CARE SYSTEM PERSPECTIVE
Fujii RK1, Mould JF2, Fernandes RA3, Furlan F1, Manfrin DF1
1Pfizer, Inc., São Paulo, SP, Brazil, 2Pfizer, Inc., New York, NY, USA, 3ANOVA-Knowledge
Translation, Rio de Janeiro, RJ, Brazil
OBJECTIVES: Currently in Brazil, acromegaly patients who fail having biochemical
control with somatostatine analogues face an unmet need. This research aims to
assess the economic impact of introducing pegvisomant to treat patients under the
public health care systemperspective.METHODS:An economicmodel considering
patients treatedwith Pegvisomant (PtwP) andpatientswithout biochemical control
(PWoC) was developed by using the available literature and Brazilian public data-
bases to evaluate the frequency of the following outcomes: Life years gained (LY),
quality adjusted life years gained (QALYs), cases of diabetes mellitus (DM), high
blood pressure (HBP), myocardial infarctions (MI), joint replacement surgeries (JR)
and number of life years without DM, HBP or MI (YWoDHM). The model was com-
posed by a decision tree portion to evaluate “JR” or “no JR” heath states, fromwhich
one-year Markov cycles were initiated considering the following health states: No
morbidity; DM; HBP; MI; HBPDM; DMMI; HBPMI; HBPDMMI; death. Proba-
bility inputs would either follow general population data to estimate biochemical
control or active acromegaly data to depict treatment failure. The time horizonwas
defined as 37 years, lifetime for PWoC since diagnose. Probabilistic sensitivity anal-
ysis was performed byMonte Carlo simulation using 10.000 iterations. 5% discount
rates were applied to costs and benefits. Values were represented in 2010 USD.
RESULTS: The values for PtwP versus PWoC were: 152.382 versus 143.935 for LY;
116.201 versus 87.227 for QALYs; 2.738 versus 6.141 for DM cases; 5.247 versus 7.244
for HBP cases; 753 versus 778 for MI cases; 67 versus 327 for JR cases and 219.319
versus149.896 for YWoDHM. ICERs for LY and QALYs were USD305.078,60 and
USD89.068,00, respectively. CONCLUSIONS: Pegvisomant has an important role in
reducing premature deaths and morbidities such as DM, HBP, JR and MI to the
PWoC under the public heath perspective in Brazil. Real world data is necessary to
identify underlying costs for the studied population.
PSY37
A UK BASED COST-EFFECTIVENESS ANALYSIS OF DASATINIB (SPRYCEL) 100MG
DAILY COMPARED TO IMATINIB (GLIVEC) 600/800MG DAILY AS THERAPY FOR
IMATINIB FAILING CHRONIC MYELOID LEUKEMIA (CML)
Taylor M1, Mealing S2, Scott D2, Clark J2, McKenna M3, Lebmeier M4, Davis C5
1York Health Economics Consortium, York, North Yorkshire, UK, 2Oxford Outcomes Ltd., Oxford,
Oxfordshire, UK, 3Health Outcomes Solutions Ltd., Brighton, UK, 4Bristol-Myers Squibb
Company, Uxbridge, Middlesex, UK, 5Bristol-Myers Squibb Ltd., Princetown, NJ, USA
OBJECTIVES: CML is a malignant orphan disease of the blood and bone marrow.
Imatinib 400mg (up to 800mg with inadequate responses) daily is currently recom-
mended for treatment of newly diagnosed patients or after failure with interfer-
on-. Dasatinib 100 mg daily has been shown to offer significant clinical efficacy in
patients failing imatinib. Its cost-effectiveness compared to imatinib 600/800 mg
has not been assessed in this patient group. METHODS: A partitioned survival/
costingmodel was developed to estimate the lifetime costs and benefits associated
with dasatinib and imatinib from a UK health service perspective using a lifetime
horizon and monthly cycles. Prognosis was assigned for dasatinib and imatinib
patients to each of five initial best clinical response categories at 12 months. Re-
sponse category specific survival was based on long-term data from IRIS clinical
trial and response rates froma phase III randomized study. Utility and resource use
data were taken from recent UK based studies and all unit/drug costs were taken
from appropriate national databases and discounted at 3.5%per annum. Probabi-
listic and deterministic sensitivity analyses were conducted to estimate the confi-
dence around the results. Outcomes are reported via incremental cost-effective-
ness ratios (ICERs); benefit is expressed as quality adjusted life years (QALYs).
RESULTS: Compared to imatinib, dasatinib offered an additional 3.53 QALYs but
incurred £90,800 of additional costs. The ICER was therefore £25,700/QALY gained.
At a threshold of £30,000/QALY gained, dasatinib had a 98.1% probability of being
cost-effective. Deterministic analysis showed that the model was sensitive to
changes in 12 month response probabilities and drug costs. The model was robust
to changes in adverse event rates/ costs, and to utility estimates. CONCLUSIONS:
Dasatinib has been shown to be clinically superior to imatinib in CML patients who
have failed imatinib treatment and is a cost-effective alternative to imatinib dose
escalation in this patient group.
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A UK BASED COST-EFFECTIVENESS ANALYSIS OF DASATINIB (SPRYCEL) 100MG
DAILY COMPARED TO IMATINIB (GLIVEC) 400MG DAILY IN NEWLY DIAGNOSED
PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML)
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OBJECTIVES: CML is a malignant blood disease. Imatinib 400mg daily is currently
recommended in newly diagnosed CML patients. Compared to imatinib, dasatinib
100mg daily has been shown to offer significant improvements in clinical efficacy
but its cost-effectiveness compared to imatinib has not been assessed in this pa-
tient group. METHODS: A partitioned survival/costing model was developed to
estimate the lifetime costs and benefits associated with dasatinib and imatinib for
a UK health service perspective using a lifetime horizon and monthly cycles. Indi-
viduals could switch from first to second line treatment at 3, 12 or 18 months for
reasons of inadequate clinical response and monthly for all other reasons. Re-
sponse category specific survival was based on long-term data from IRIS clinical
trial and response rates from a recent network-meta-analysis. Utility and resource
use datawere taken fromUK based studies and all unit/drug costs were taken from
national databases and discounted at 3.5% per annum. Probabilistic and determin-
istic sensitivity analyses were conducted to estimate the confidence around the
results. Outcomes are reported via incremental cost-effectiveness ratios (ICERs),
benefit is expressed as quality adjusted life years (QALYs). RESULTS: Compared to
imatinib, dasatinib offered an additional 0.71 QALYs (95% CI -0.15, 1.68) but in-
curred £17,646 of additional costs (95%CI -£24,259, £57,947). The ICERwas therefore
£24,922/QALY gained. At a threshold of £30,000/QALY gained, dasatinib had a 62.6%
probability of being cost-effective. Deterministic analysis showed that the model
was sensitive to changes in the 12-month response probabilities and drug costs.
When trial observed dose intensities were used, the ICER was £13,400/QALY
gained. The model was robust to changes in adverse event rates/ costs, and utility
estimates. CONCLUSIONS: Dasatinib has been shown to be clinically superior to
imatinib in newly diagnosed CML patients and is a cost-effective alternative to
imatinib in this patient group.
SYSTEMIC DISORDERS/CONDITIONS – Patient-Reported Outcomes & Patient
Preference Studies
PSY39
DOSING AND REFILL COMPLIANCE IN ANKYLOSING SPONDYLITIS PATIENTS
TREATED WITH GOLIMUMAB
Ellis L1, Haas S2, Tandon N1
1Janssen Scientific Affairs, LLC, Horsham, PA, USA, 2S2 Statistical Solutions, Inc., Cincinnati, OH,
USA
OBJECTIVES: This study reports dosing and refill compliance observed in goli-
mumab (GLM)-treated ankylosing spondylitis (AS) patients.METHODS: This retro-
spective analysis assessed GLM use in adult AS patients with2 GLM prescriptions
between April 24, 2009 and December 31, 2010;  1 AS diagnosis during the study
period; continuous activity in the Source® LX database (6 months before; 6
months after the index GLM prescription); and a 28-31 day GLM supply. Refill com-
pliance was defined as 1 week of the expected 28-31 day (d) interval. The percent
of compliant GLM refill intervals and the percent of patients demonstrating refill
compliance at the 6th GLM dose were assessed. Data were summarized with de-
scriptive statistics. RESULTS: A total of 99 AS patients and 559 GLM refill intervals
were studied. The sample was 53% male; mean age of 44 years with 72% bio-
experienced. A 50 mg GLM dose occurred in 99% of all fills. The mean  SD refill
interval for the populationwas 35.121.0 dwith amedian of 30 d. The refill interval
of bio-experienced patients (34.818.7 d; median 30 d) was similar to bio-naïve
patients (35.825.8 d; median 31 d). Refill compliance was observed in 79% of all
intervals. Refill compliance at the 6th GLM dose was achieved by 83% of patients
overall.CONCLUSIONS: In this retrospective administrative claims analysis, 99% of
GLM doses were 50 mg with approximately once monthly refill intervals. Overall
refill compliance was observed in nearly 80% of all GLM refills and in greater than
80% of AS patients at the sixth GLM dose. Median refill interval and refill compli-
ance appeared similar in bio-experienced and bio-naïve subgroups. Further study
of these trends using additional data sources are desired to substantiate these
preliminary findings.
PSY40
ARE NEUROPATHIC PAIN (NP) TREATMENT BENEFITS REFLECTED IN THE SELF
ASSESSMENT OF TREATMENT (SAT) QUESTIONNAIRE?
Wiklund I1, Holmstrom S2, Wyrwich K3, Devine M3, Stoker M2
1United BioSource Corporation, London, UK, 2Astellas Pharma Global Development, Leiderdorp,
The Netherlands, 3United BioSource Corporation, Bethesda, MD, USA
OBJECTIVES: To understand how patients perceived the relevance and ease of
understanding of the questions included in SAT questionnaire to reflect key pa-
tient-reported outcomes of NP treatments and to provide recommendations mod-
ifications based on patient clinician interviews.METHODS: Semi-structured inter-
views were conducted with clinicians and NP patients to inform on treatment
attributes and pain impacts. Patients were debriefed on the SAT, a 5-item scale
evaluating pain, activity level, quality of life (QL) and satisfaction with treatment
(recommend treatment and undergo treatment again). SAT has a recall period
reflecting back to initiation of treatment. The qualitative analysis software AT-
LAS.ti 5.0 was used to analyze patient transcripts. Changes to SAT underwent
debriefings. RESULTS: Three NP clinicians and 44 patients (20 painful diabetic neu-
A105V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 1 – A 2 5 6
